Evidence map›Paper›PMID 28285168›Full record

ArticleJournal of microbiological methods2017

Design and use of mouse control DNA for DNA biomarker extraction and PCR detection from urine: Application for transrenal Mycobacterium tuberculosis DNA detection.

Hali Bordelon, Keersten M Ricks, Megan E Pask, Patricia K Russ, Francesca Solinas, Mark L Baglia, Philip A Short, Andrew Nel, Jonathan Blackburn, Keertan Dheda and 5 more

Abstract read
In one paragraph

Article in Journal of microbiological methods, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hali BordelonDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
Keersten M RicksDepartment of Chemistry, Vanderbilt University, Nashville, TN, USA.
Megan E PaskDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
Patricia K RussDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
Francesca SolinasDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
Mark L BagliaDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
Philip A ShortDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
Andrew NelInstitute of Infectious Disease and Molecular Medicine, Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa.
Jonathan BlackburnInstitute of Infectious Disease and Molecular Medicine, Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa; Tuberculosis Center, Department of Medicine, Division of Infectious Diseases and Institute for Global Health, Vanderbilt University School of Medicine, Nashville, TN, USA.
Keertan DhedaLung Infection and Immunity Unit, University of Cape Town, Cape Town, South Africa.
Carlos Zamudiode Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.
Tatiana Cáceresde Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.
David W WrightDepartment of Chemistry, Vanderbilt University, Nashville, TN, USA; Tuberculosis Center, Department of Medicine, Division of Infectious Diseases and Institute for Global Health, Vanderbilt University School of Medicine, Nashville, TN, USA.
Frederick R HaseltonDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA; Department of Chemistry, Vanderbilt University, Nashville, TN, USA; Tuberculosis Center, Department of Medicine, Division of Infectious Diseases and Institute for Global Health, Vanderbilt University School of Medicine, Nashville, TN, USA.
April C PettitDivision of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA; Tuberculosis Center, Department of Medicine, Division of Infectious Diseases and Institute for Global Health, Vanderbilt University School of Medicine, Nashville, TN, USA. Electronic address: april.pettit@vanderbilt.edu.

Funding

Vanderbilt-Zambia Network for Innovation in Global Health TechnologiesD43TW009348 · FIC · VANDERBILT UNIVERSITY · PI HASELTON, FREDERICK R, HEIMBURGER, DOUGLAS CORBETT · 2012 to 2016
$1.7M
Tuberculosis Risk and Highly Active Antiretroviral Therapy InitiationK08AI104352 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PETTIT, APRIL · 2013 to 2016
$541k
FIC NIH HHS D43 TW009348NIAID NIH HHS K08 AI104352
6 · The paper itself

Abstract

Urine samples are increasingly used for diagnosing infections including Escherichia coli, Ebola virus, and Zika virus. However, extraction and concentration of nucleic acid biomarkers from urine is necessary for many molecular detection strategies such as polymerase chain reaction (PCR). Since urine samples typically have large volumes with dilute biomarker concentrations making them prone to false negatives, another impediment for urine-based diagnostics is the establishment of appropriate controls particularly to rule out false negatives. In this study, a mouse glyceraldehyde 3-phosphate dehydrogenase (GAPDH) DNA target was added to retrospectively collected urine samples from tuberculosis (TB)-infected and TB-uninfected patients to indicate extraction of intact DNA and removal of PCR inhibitors from urine samples. We tested this design on surrogate urine samples, retrospective 1milliliter (mL) urine samples from patients in Lima, Peru and retrospective 5mL urine samples from patients in Cape Town, South Africa. Extraction/PCR control DNA was detectable in 97% of clinical samples with no statistically significant differences among groups. Despite the inclusion of this control, there was no difference in the amount of TB IS6110 Tr-DNA detected between TB-infected and TB-uninfected groups except for samples from known HIV-infected patients. We found an increase in TB IS6110 Tr-DNA between TB/HIV co-infected patients compared to TB-uninfected/HIV-infected patients (N=18, p=0.037). The inclusion of an extraction/PCR control DNA to indicate successful DNA extraction and removal of PCR inhibitors should be easily adaptable as a sample preparation control for other acellular sample types.

Indexed as

Genetic MarkersAnimalsBase SequenceCoinfectionDNAGene TargetingGlyceraldehyde-3-Phosphate DehydrogenasesHIV InfectionsHumansMiceMolecular Diagnostic TechniquesMycobacterium tuberculosisPeptide FragmentsPolymerase Chain ReactionRetrospective StudiesSensitivity and SpecificityDNAGenetic Markersglyceraldehyde 3-phosphate dehydrogenase (304-313)Glyceraldehyde-3-Phosphate DehydrogenasesPeptide Fragments

Identifiers

PMID28285168
PMCPMC5421388

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.